72 articles
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
A Phase 3 trial pits monthly lerodalcibep against evolocumab in homozygous familial hypercholesterolemia patients over 24 weeks.
A Phase 2 trial pits NNC0385-0434 tablets against evolocumab injections in high-risk cardiovascular patients — could a daily pill replace the shot?
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
A completed Phase 3 trial evaluates obicetrapib added to maximum lipid-lowering therapy in patients with familial hypercholesterolemia and ASCVD.
A Phase 3 trial examines whether bococizumab slashes LDL in statin-treated patients at elevated cardiovascular risk.
A new study reveals how pancreatic cancer hijacks lipid metabolism to evade immunity—and how targeting SREBP1-PCSK9 reverses this resistance.
A 2026 practical review exposes critical gaps in lipid management and outlines updated strategies to slash cardiovascular risk.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
A forward genetic screen in mice reveals HELZ2 helicase degrades APOB mRNA, linking RNA stability to fatty liver disease and heart disease risk.
A simulation of 250,000 adults finds using apoB goals to guide lipid-lowering therapy costs just $30,300 per QALY gained vs. non-HDL-C, making it highly cost-effective.
Even with optimal LDL control, remnant cholesterol, Lp(a), and apoB drive ongoing ASCVD risk — and new therapies are emerging to address them.
